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Letters
Cerebellar ataxia associated to anti-glutamic 
acid decarboxylase autoantibody (anti-GAD)
Partial improvement with intravenous immunoglobulin therapy
José Luiz Pedroso, Pedro Braga-Neto, Livia Almeida Dutra, Orlando G.P. Barsottini
High levels of glutamic acid decarboxylase (GAD) au-
toantibody may be observed in a few patients with spo-
radic ataxias, supporting an autoimmune pathogenesis 
of the cerebellar syndrome1.  
We describe a patient with GAD autoantibody (anti-
GAD) ataxia and type 1 diabetes with partial improve-
ment of neurological symptoms after immunoglobulin 
therapy.
CASE
A 51 year-old man presented to our hospital with 
nine-years history of progressive gait instability, diffi-
culty walking and insulin dependent diabetes. Family 
history was unremarkable. On examination, there was 
ataxic gait, severe limb and trunk ataxia, and dysarthria. 
He scored 65 in International Cooperative Ataxia Rating 
Scale (ICARS) and 20 in Scale for Assessment and Rating 
of Ataxia (SARA), an objective toll for evaluating ataxia 
severity. Electroneuromyography was normal. Blood 
tests, thyroid function, antibodies and serologic tests 
were normal, except for high serum anti-GAD: 3.2 U/
mL (normal range: <1.0 U/mL). Brain magnetic reso-
nance imaging (MRI) disclosed mild cerebellar atrophy. 
Genetic tests for spinocerebellar ataxias type 1, 2, 3 and 6 
were negative. Immunoglobulin therapy was started, 0.4 
g/Kg daily, for five consecutive days every month, during 
three months. Partial improvement of motor symptoms 
was observed four months after the beginning of treat-
ment: he scored 37 in ICARS and 16 in SARA. 
DISCUSSION
GAD is the enzyme that catalyses the conversion of 
glutamic acid to the neurotransmitter gamma-amino bu-
tyric acid. Neurological disorders related to GAD anti-
bodies include cerebellar ataxia, palatal myoclonus, stiff-
person syndrome, drug-resistant epilepsy and also limbic 
encephalitis1,2. Experimental data have suggested a direct 
excitotoxic effect of GAD antibodies on Purkinje cells to 
explain cerebellar involvement, although there is contro-
versy regarding the exact pathogenic role of neurological 
disorders related to GAD antibodies2. 
The clinical spectrum of anti-GAD ataxia comprises 
slowly progressive cerebellar ataxia syndrome evolving 
in months or years, associated with cerebellar atrophy 
on brain MRI in about half of cases. Cerebrospinal fluid 
analyses frequently detects oligoclonal bands2,3. Diag-
nosis is supported by high serum GAD antibodies. As-
sociation with late-onset type 1 diabetes and other auto-
immune disorders is frequently seen2. On the other hand, 
a Brazilian series have demonstrated that around 50% of 
long-duration type 1 diabetes subjects without neurolog-
ical symptoms presented high titters of GAD antibodies4. 
Although positive, our patient presented lower levels of 
anti-GAD antibodies compared to other case reports2.
Other case reports have suggested that immuno-
therapy might be useful in autoantibody-positive cer-
ebellar ataxia, but this still subject of controversy. Re-
cently, Nanri et al. described a clear improvement in 
ICARS in two patients with anti-GAD ataxia using im-
munoglobulin. Additionally, steroids and immunosup-
pressive agents might also be used5. 
This short report and analyses of previous data sug-
gest that testing for GAD antibodies may be indicated 
in patients with sporadic cerebellar ataxia, particularly 
when type 1 diabetes is present. Treatment with immu-
noglobulin or other immunosuppressive agents might be 
considered in these cases. 
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